<DOC>
	<DOCNO>NCT02209506</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability single multiple oral dosing MLN3126 ascend dos healthy non-Japanese Japanese participant .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics , Pharmacodynamics MLN3126 Healthy Japanese Non-Japanese Participants</brief_title>
	<detailed_description>MLN3126 test find safe well-tolerated dose healthy people assess MLN3126 process body . In total , approximately 64 participant enrol study . This study compose 2 part : Part A healthy non-Japanese participant Part B healthy Japanese participant . Each part consist 4 Cohorts 8 participant Cohort . In Cohort , 6 participant receive MLN3126 2 participant receive match placebo within 30 minute start standard breakfast . The start dose 100 mg follow dos 300 mg , 800 mg , dose determine study . Progression next dose level occur previous dose level consider safe well tolerate . This single-center trial conduct United States . The overall time participate study 20 day . All participant contact telephone 7 day last dose study drug follow-up assessment . Due toxicology finding long-term animal study , Takeda make decision terminate study . No clinically significant safety and/or tolerability issue observe reported participant expose MLN3126 .</detailed_description>
	<criteria>Part A ( Healthy nonJapanese participant ) : 1 . In opinion investigator , participant capable understand comply protocol requirement . 2 . The participant , applicable , participant 's legally acceptable representative sign date write , informed consent form require privacy authorization prior initiation study procedure , include request participant fast laboratory evaluation . 3 . Is male female adult , 18 55 year age , inclusive , time inform consent study drug dose . 4 . Is healthy adult male female participant evidence medical history , complete physical examination , vital sign , electrocardiogram ( ECG ) , safety laboratory evaluation . 5 . Weighs least 45 kg body mass index ( BMI ) 18 30 kg/m^2 inclusive Screening . 6 . A male participant nonsterilized sexually active female partner childbearing potential agrees use adequate contraception signing inform consent throughout duration study 12 week last dose . 7 . A female participant childbearing potential sexually active nonsterilized male partner agree routinely use adequate contraception signing inform consent throughout duration study next postconfinement menstruation . In addition , participant must advise donate ova period . Part B ( Healthy Japanese participant ) : 1 . In opinion investigator , participant capable understand comply protocol requirement . 2 . The participant , applicable , participant 's legally acceptable representative sign date write , informed consent form require privacy authorization prior initiation study procedure , include request participant fast laboratory evaluation . 3 . Is male female adult , 20 55 year age , inclusive , time inform consent study drug dosing , Japanese descent ( bear Japanese parent grandparent live outside Japan le 15 year ) , maintain Japanese diet lifestyle . 4 . Is healthy adult male female participant evidence medical history , complete physical examination , vital sign , ECG , safety laboratory evaluation . 5 . Weighs least 45 kg BMI 18 28 kg/m^2 inclusive Screening . 6 . A male participant nonsterilized sexually active female partner childbearing potential agrees use adequate contraception signing inform consent throughout duration study 12 week last dose . 7 . A female participant childbearing potential sexually active nonsterilized male partner agree routinely use adequate contraception signing inform consent throughout duration study next postconfinement menstruation . In addition , participant must advise donate ova period . Part A ( Healthy nonJapanese participant ) Part B ( Healthy Japanese participant ) : 1 . Has receive investigational compound within 30 day 5 halflives investigational compound , whichever longer , prior first dose study medication . 2 . Has receive MLN3126 previous clinical study . 3 . Is immediate family member , study site employee , dependant relationship study site employee involve conduct study ( eg , spouse , parent , child , sibling ) may consent duress . 4 . Has uncontrolled , clinically significant neurologic , cardiovascular , pulmonary , hepatic , renal , metabolic , gastrointestinal ( GI ) , endocrine disease allergic skin rash abnormality may impact ability participant participate potentially confound study result . 5 . Has know hypersensitivity component formulation MLN3126 . 6 . Has positive urine drug result drug abuse Screening Checkin ( Day 1 ) . 7 . Has history drug abuse ( define illicit drug use ) history alcohol abuse ( define 4 alcoholic beverage per day ) within 1 year prior Screening Visit unwilling agree abstain alcohol drug throughout study . 8 . Has take exclude medication , supplement , food product list Excluded Medications Dietary Products section protocol . 9 . If female , participant pregnant lactate intend become pregnant study , include timeframe participant 's next postconfinement menstruation participate study . 10 . If male , participant intend donate sperm course study 12 week thereafter . 11 . Has current recent ( within 6 month ) GI disease would expect influence absorption drug ( ie , history malabsorption , surgical intervention know impact absorption [ eg , bariatric surgery bowel resection ] , esophageal reflux , peptic ulcer disease , erosive esophagitis , frequent [ per week ] occurrence heartburn ) . 12 . Has Gilbert 's syndrome bilirubin level 1.2x upper limit normal ( ULN ) . 13 . Has history cancer , except basal cell carcinoma , remission least 5 year prior Day 1 . 14 . Has positive test result hepatitis B surface antigen ( HBsAg ) antibody hepatitis C virus ( antiHCV ) Screening know history human immunodeficiency virus infection . 15 . Has use nicotinecontaining product ( include limit cigarette , pipe , cigar , chew tobacco , nicotine patch nicotine gum ) within 28 day prior Checkin ( Day 1 ) . Cotinine test positive Screening Checkin ( Day 1 ) . 16 . Has poor peripheral venous access . 17 . Has donate lose 450 mL blood volume ( include plasmapheresis ) transfusion blood product within 45 day prior Day 1 . 18 . Has Screening Checkin ( Day 1 ) abnormal ( clinically significant ) electrocardiogram ( ECG ) . Entry participant abnormal ( clinically significant ) ECG must approve , document signature principal investigator . 19 . Has QT interval Fridericia correction method ( QTcF ) &gt; 430 millisecond ( m ) men &gt; 450 ms woman PR outside range 120 210 m confirm upon repeat test within maximum 30 minute , Screening Visit Checkin ( Day 1 ) . 20 . Has abnormal Screening Checkin ( Day 1 ) laboratory value suggest clinically significant underlying disease participant follow laboratory abnormality : Alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) &gt; 1.5 ULN .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>MLN3126</keyword>
</DOC>